Image from Google Jackets

A Different kind of mm : a rare case of mm revealed / Jennelyn A. Sanchez.

By: Language: English Publication details: Fairview, Quezon City Department of Internal Medicine, FEU-NRMF, 2016Description: photos (black and white); (in folder)Content type:
  • rdacontent
Media type:
  • rdamedia
Carrier type:
  • rdacarrier
LOC classification:
  • MED20160011
Summary: ABSTRACT: Multiple myeloma is a malignant disease characterized by plasmacytosis, paraprotien production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the clinical features include suppression of humoral-and cell-mediated immunity, elevation of IL-6, abnormalities of the bone marrow microenvironment, and increased osteoclastic activity. Overwhelming predictors of prognosis include albumin, β2-microglobulin, and chomosomal karyotype. With modern, intensive therapy including autologous hematopoietic stem cell transplantation, the median survival is approximately 5 yr. The disease is incurable and eventually relapse; requiring salvage therapy. The development of newer agents such as thalidomide, bortezomid, and lenalidomide-drugs that interfere with several of the complex pathophysiologic steps-has improved the outlook of relapsed disease significantly. Current studies are directed at exploring the use of these novel agents earlier in the course of therapy, development of newer targeted therapies, and the use of gene expression profiling to individualize therapy.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Call number Status Date due Barcode
Research Far Eastern University - Nicanor Reyes Medical Foundation Research MED20160011 (Browse shelf(Opens below)) Available R000587

Includes bibliographical references.

ABSTRACT: Multiple myeloma is a malignant disease characterized by plasmacytosis, paraprotien production, bone lesions, hypercalcemia, susceptibility to infections, and renal impairment. The underlying pathophysiologic phenomena of the clinical features include suppression of humoral-and cell-mediated immunity, elevation of IL-6, abnormalities of the bone marrow microenvironment, and increased osteoclastic activity. Overwhelming predictors of prognosis include albumin, β2-microglobulin, and chomosomal karyotype. With modern, intensive therapy including autologous hematopoietic stem cell transplantation, the median survival is approximately 5 yr. The disease is incurable and eventually relapse; requiring salvage therapy. The development of newer agents such as thalidomide, bortezomid, and lenalidomide-drugs that interfere with several of the complex pathophysiologic steps-has improved the outlook of relapsed disease significantly. Current studies are directed at exploring the use of these novel agents earlier in the course of therapy, development of newer targeted therapies, and the use of gene expression profiling to individualize therapy.

Research - Department of Medicine

There are no comments on this title.

to post a comment.